Page last updated: 2024-12-05

oxolinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxolinic acid is a synthetic antibacterial agent that belongs to the quinolone class of drugs. It is effective against a wide range of gram-negative bacteria, including Escherichia coli, Salmonella, and Shigella. Oxolinic acid acts by inhibiting the activity of bacterial DNA gyrase, an enzyme essential for DNA replication. It is used to treat urinary tract infections, but its use is limited due to the emergence of resistant strains. Synthesis of oxolinic acid involves a multi-step process, starting with the reaction of 4-hydroxyquinoline with ethyl chloroformate. The resulting product is then reacted with 2-amino-3-hydroxypyridine to form oxolinic acid. Oxolinic acid has been studied extensively for its potential as an antibacterial agent, as well as its effects on other biological processes. For example, it has been shown to have anti-inflammatory and anti-cancer properties. The development of resistance to oxolinic acid is a major concern, as this could limit its effectiveness in treating bacterial infections.'

quinolone antibiotic : An organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4628
CHEMBL ID416755
CHEBI ID138856
SCHEMBL ID24445
MeSH IDM0015656

Synonyms (193)

Synonym
MLS000028501
DIVK1C_000659
KBIO1_000659
dioxacin
acide oxolinique [inn-french]
hsdb 3243
einecs 238-750-8
ultibid
acidum oxolinicum [inn-latin]
acido ossolico [dcit]
nsc 110364
acido oxolinico [inn-spanish]
1,3-dioxolo(4,5-g)quinoline-7-carboxylic acid, 5-ethyl-5,8-dihydro-8-oxo-
cistopax
ccris 6301
5-ethyl-5,8-dihydro-8-oxo-1,3-dioxolo(4,5-g)quinoline-7-carboxylic acid
tiurasin
ossian
brn 0620635
pietil
1-ethyl-6,7-methylenedioxy-4-quinolone-3-carboxylic acid
urotrate
1-ethyl-1,4-dihydro-6,7-methylenedioxy-4-oxo-3-quinolinecarboxylic acid
starner
uritrate
uro-alvar
oxoboi
orthurine
s-0208 ,
gramurin
EU-0100952
oxolinic acid, quinolone antibiotic
SPECTRUM_001397
PRESTWICK_629
lopac-o-0877
cas-14698-29-4
NCGC00015762-02
NCGC00015762-01
BSPBIO_003079
LOPAC0_000952
OPREA1_169598
BSPBIO_000145
PRESTWICK3_000193
PRESTWICK2_000193
IDI1_000659
nidantin
1,5-g]quinoline-7-carboxylic acid, 5-ethyl-5,8-dihydro-8-oxo-
1-ethyl-1,7-methylenedioxy-4-oxo-3-quinolinecarboxylic acid
5-ethyl-5,3-dioxolo[4,5-g]quinoline-7-carboxylic acid
w 4565
oxolinic
nsc110364
emyrenil
oksaren
utibid
OXOLINIC ACID ,
prodoxol
nsc-110364
uroxol
prodoxal
14698-29-4
wln: t c566 do fo jn mv ehj j2 lvq
5-ethyl-5,8-dihydro-8-oxo-1,3-dioxolo[4,5-g]quinoline-7-carboxylic acid
1,3-dioxolo[4,5-g]quinoline-7-carboxylic acid, 5-ethyl-5,8-dihydro-8-oxo-
inchi=1/c13h11no5/c1-2-14-5-8(13(16)17)12(15)7-3-10-11(4-9(7)14)19-6-18-10/h3-5h,2,6h2,1h3,(h,16,17
5-ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid
5-ethyl-8-oxo-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid
oxolinic acid (usan/inn)
aqualinic (tn)
D02301
NCGC00093361-04
NCGC00093361-03
smr000058314
KBIO2_004445
KBIO2_001877
KBIOGR_000625
KBIO3_002579
KBIOSS_001877
KBIO2_007013
SPECTRUM4_000073
SPBIO_002066
NINDS_000659
SPECTRUM3_001490
SPBIO_000866
SPECTRUM2_000933
PRESTWICK1_000193
PRESTWICK0_000193
SPECTRUM1502030
SPECTRUM5_001176
BPBIO1_000161
NCGC00093361-05
NCGC00093361-02
NCGC00015762-03
NCGC00015762-05
O 0877
w-4565; 5,8-dihydro-5-ethyl-8-oxo-1,3-dioxolo[4,5-g]quinoline-7-carboxylic acid
HMS2092P09
acide oxolinique
acidum oxolinicum
CHEBI:138856 ,
acido oxolinico
NCGC00015762-11
CHEMBL416755
aqualinic
w-4565 ,
AKOS000282622
HMS502A21
HMS1568H07
HMS1921F12
STK801351
NCGC00015762-06
A808577
HMS3262P06
HMS2095H07
acid, oxolinic
unii-l0a22b22ft
oxolinic acid [usan:inn:ban]
l0a22b22ft ,
5-ethyl-8-oxo-5-hydro-2h-1,3-dioxoleno[4,5-g]quinoline-7-carboxylic acid
NCGC00260333-01
tox21_202787
BBL009934
5,8-dihydro-5-ethyl-8-oxo-1,3-dioxolo[4,5-g]quinoline-7-carboxylic acid
pharmakon1600-01502030
nsc-758177
nsc758177
tox21_110216
dtxsid1021089 ,
dtxcid101089
acido ossolico
S4537 ,
CCG-39666
NCGC00015762-10
NCGC00015762-04
NCGC00015762-09
NCGC00015762-07
NCGC00015762-08
FT-0637128
LP00952
5-ethyl-8-oxo-5,8-dihydro-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid
F3351-0487
oxolinic acid [mi]
oxolinic acid [usan]
oxolinic acid [who-dd]
oxolinic acid [ep monograph]
oxolinic acid [hsdb]
oxolinic acid [mart.]
oxolinic acid [inn]
5-ethyl-5,8-dihydro-8-oxo(1,3)dioxolo(4,5-g)quinoline-7-carboxylic acid
SCHEMBL24445
tox21_110216_1
NCGC00015762-13
NCGC00261637-01
CS-4499
tox21_500952
quinolone antibiotic
1.4-dihydro-1-ethyl-6,7-methylenedioxy-4-oxoquinoline-3-carboxylic acid
5-ethy1-5,8-dihydro-8-oxo-1,3-dioxolo[4,5]quinoline-7-carboxylic acid
W-108119
inoxyl
urinox
5-ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid #
HY-B1002
mfcd00056775
oxolinic acid, analytical standard
sr-01000076042
SR-01000076042-1
VU0243182-3
5-ethyl-8-oxo-2h,5h,8h-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid
oxolinic acid, european pharmacopoeia (ep) reference standard
SR-01000076042-6
SR-01000076042-4
SBI-0050926.P003
HMS3712H07
Q287840
SY066716
DB13627
16172-03-5
oxolinic acid impurity b
AS-12087
BRD-K73394555-001-08-6
SDCCGSBI-0050926.P004
NCGC00015762-17
oxolinic-acid
AC8065
acidum oxolinicum (inn-latin)
5-ethyl-8-oxo-5,8-dihydro(1,3)dioxolo(4,5-g)quinoline-7-carboxylic acid
oxolinic acid (mart.)
oxolinic acid (ep monograph)
5-ethyl-8-oxo-5,8-dihydro (1,3) dioxolo (4,5-g) quinoline-7-carboxylic acid
acido oxolinico (inn-spanish)
acide oxolinique (inn-french)
j01mb05

Research Excerpts

Overview

Oxolinic acid (OA) is a widely used quinolone antibiotic in aquaculture.

ExcerptReferenceRelevance
"Oxolinic acid (OA) is a widely used quinolone antibiotic in aquaculture. "( Oxolinic Acid Binding at Goethite and Akaganéite Surfaces: Experimental Study and Modeling.
Boily, JF; Hanna, K; Marsac, R; Martin, S, 2016
)
3.32

Effects

ExcerptReferenceRelevance
"But oxolinic acid has an important advantage over them, that is, the increase in radioresistance it induces persists for several hours."( [Radioprotective properties of oxolinic acid].
Iashunskiĭ, VG; Leonova, TS; Terekhov, AV; Zherebchenko, PG; Znamenskiĭ, VV,
)
0.9
"But oxolinic acid has an important advantage over them, that is, the increase in radioresistance it induces persists for several hours."( [Radioprotective properties of oxolinic acid].
Iashunskiĭ, VG; Leonova, TS; Terekhov, AV; Zherebchenko, PG; Znamenskiĭ, VV,
)
0.9

Actions

Oxolinic acid was shown to produce a radioprotective effect on mice. It also had a therapeutic action on rats and hamsters. Oxolinic Acid displays a solubility maximum in each solvent mixture.

ExcerptReferenceRelevance
"Oxolinic acid displays a solubility maximum in each solvent mixture at solubility parameter values of 32 and 22 MPa(1/2)."( A cosolvency model to predict solubility of drugs at several temperatures from a limited number of solubility measurements.
Bustamante, P; Chan, HK; Clark, BJ; Jouyban, A; Romero, S, 2002
)
1.04
"Oxolinic acid was shown to produce a radioprotective effect on mice and a therapeutic radioprotective action on rats and hamsters. "( [Radioprotective properties of oxolinic acid].
Iashunskiĭ, VG; Leonova, TS; Terekhov, AV; Zherebchenko, PG; Znamenskiĭ, VV,
)
1.86

Toxicity

ExcerptReferenceRelevance
" It was found that norfloxacin, cinoxacin and oxolinic acid are safe and effective against Escherichia coli, Klebsiella and Proteus, the commonly encountered organisms in urinary tract infections."( Experiences on the efficacy and safety of nalidixic acid, oxolinic acid, cinoxacin and norfloxacin in the treatment of urinary tract infections (UTI).
El Bokl, MA; Osman, LM; Sabbour, MS,
)
0.63
"The degradation of veterinary drugs approved for use in aquaculture is very important in the evaluation of the impact of these drugs on the environment and to ensure safe food production."( Environmental impact assessment of veterinary drug on fish aquaculture for food safety.
Kwon, JW, 2016
)
0.43

Pharmacokinetics

Oxolinic acid and vetoquinol, the carbitol ester of oxolinic Acid, were studied after intravenous (i.e. intravascular) administration to Atlantic salmon.

ExcerptReferenceRelevance
" The aims of this study were to examine and compare the pharmacokinetic properties of the quinolones oxolinic acid, flumequine, sarafloxacin, and enrofloxacin after intravascular and oral administration to Atlantic salmon (Salmo salar) by using identical experimental designs."( Comparative single-dose pharmacokinetics of four quinolones, oxolinic acid, flumequine, sarafloxacin, and enrofloxacin, in Atlantic salmon (Salmo salar) held in seawater at 10 degrees C.
Horsberg, TE; Martinsen, B, 1995
)
0.75
" The pharmacokinetic process was not significantly sex-influenced."( Pharmacokinetics of a discontinuous absorption process of oxolinic acid in turbot, Scophthalmus maximus, after a single oral administration.
Blanc, G; Poher, I, 1998
)
0.54
"The pharmacokinetic properties of the antibacterial agent oxolinic acid and vetoquinol, the carbitol ester of oxolinic acid, were studied after intravenous (i."( A single-dose pharmacokinetic study of oxolinic acid and vetoquinol, an oxolinic acid ester, in cod, Gadus morhua L., held in sea water at 8 degrees C and in vitro antibacterial activity of oxolinic acid against Vibrio anguillarum strains isolated from di
Bergh, O; Ervik, A; Samuelsen, OB, 2003
)
0.83

Compound-Compound Interactions

ExcerptReferenceRelevance
"This study investigated the synergistic effects of oxolinic acid (OA) combined with oxytetracycline (OTC) on white shrimp (Penaeus vannamei)."( Synergistic effects of dietary oxolinic acid combined with oxytetracycline on nonspecific immune responses and resistance against Vibrio parahaemolyticus infection of white shrimp (Penaeus vannamei).
Chang, JJ; Chen, BY; Chen, YY; Huang, HT; Lin, YR; Nan, FH; Wu Chang, YH, 2022
)
1.26

Bioavailability

Oxolinic acid was found to be well absorbed by gilthead sea bream (92%) and sharpsnout sea Bream (88%) while the absorption of OTC was lower in both species. The pharmacokinetics and bioavailability of oxolinic Acid and oxytetracycline were studied in rainbow trout.

ExcerptReferenceRelevance
" The pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline were studied in rainbow trout at a water temperature of 16 degrees C after intravascular (10 and 20 mg/kg, respectively) and oral (75 mg/kg) dosing."( Comparative pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline in rainbow trout (Oncorhynchus mykiss).
Björklund, HV; Bylund, G, 1991
)
0.79
"A study was performed on the serum bioavailability and tissue elimination of oxolinic acid in the trout."( Oxolinic acid in the trout: bioavailability and tissue residues.
Ambroggi, G; Archimbault, P; Nicolas, S, 1988
)
1.95
" Bioavailability is enhanced by food or propantheline."( Nitrofurantoin.
D'Arcy, PF,
)
0.13
" The bioavailability varied considerably among the four quinolones."( Comparative single-dose pharmacokinetics of four quinolones, oxolinic acid, flumequine, sarafloxacin, and enrofloxacin, in Atlantic salmon (Salmo salar) held in seawater at 10 degrees C.
Horsberg, TE; Martinsen, B, 1995
)
0.53
" The oral bioavailability was 27."( Pharmacokinetics of a discontinuous absorption process of oxolinic acid in turbot, Scophthalmus maximus, after a single oral administration.
Blanc, G; Poher, I, 1998
)
0.54
" Oxolinic acid was found to be well absorbed by gilthead sea bream (92%) and sharpsnout sea bream (88%) while the absorption of OTC was found to be considerably lower in both species (27 and 40%, respectively)."( Potential drug (oxytetracycline and oxolinic acid) pollution from Mediterranean sparid fish farms.
Alexis, M; Nengas, I; Rigos, G; Troisi, GM, 2004
)
1.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The method was applied to some dosage forms, and the results obtained had good correlation with those from turbidity, wet sieving or dissolution test."( Laser diffraction estimation of particle size distribution of slightly water-soluble drugs coexisting with additives: application to solid dosage forms.
Kobayashi, M; Nishioka, Y; Noda, K; Ohsawa, T, 1992
)
0.28
" Here we report dose-response data on the mutagenicity and toxicity of m-AMSA in T4 rFC11."( Mutagenicity of topoisomerase-active agents in bacteriophage T4.
DeMarini, DM; Lawrence, BK, 1988
)
0.27
" No clear dose-response curve was obtained."( Evaluation of the DNA-damaging and mutagenic activity of oxolinic and pipemidic acids by the granuloma pouch assay.
Maura, A; Pino, A, 1988
)
0.27
" Especially, all of the cases dosed with miloxacin over 34 mg/kg in a day showed excellent or good results."( [Chemotherapy on the biliary tract infections. XIII. Miloxacin, a novel chemotherapeutic agent, its excretion into bile and clinical effect on the biliary tract infections (author's transl)].
, 1981
)
0.26
"Simple assays for extraction and determination of the concentrations of the antibiotics oxytetracycline, oxolinic acid, and flumequine in a drug dosage form for farmed fish are described."( Extraction and analysis by high-performance liquid chromatography of antibiotics in a drug delivery system for farmed fish.
Rogstad, A; Weng, B, 1993
)
0.5
" The aim of this study was to determine both its elimination into eggs, following oral dosing through the drinking water (12 mg/kg/d) or diet (13 mg/kg/d) for 5 d and its plasma concentrations."( Elimination of oxolinic acid in eggs after oral treatment of laying hens.
Roudaut, B, 1998
)
0.65
" These data were integrated with production records for sparids, drug dosage regimes and treatment frequency information to calculate potential annual drug release to the aquatic environment from Greek fish farms."( Potential drug (oxytetracycline and oxolinic acid) pollution from Mediterranean sparid fish farms.
Alexis, M; Nengas, I; Rigos, G; Troisi, GM, 2004
)
0.6
" Medication commenced 1day following challenge and was performed on days 1, 3 and 5 post-challenge at a dosage of 20mgL(-1) for 2h for bath treatments, while two doses each of 750 nauplii per fish were administered daily for five consecutive days in oral treatments."( Treatment of vibriosis in European sea bass larvae, Dicentrarchus labrax L., with oxolinic acid administered by bath or through medicated nauplii of Artemia franciscana (Kellogg): efficacy and residual kinetics.
Karagiannis, V; Niopas, I; Touraki, M, 2012
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
antibacterial drugA drug used to treat or prevent bacterial infections.
enzyme inhibitorA compound or agent that combines with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
quinolinemonocarboxylic acidAny aromatic carboxylic acid that contains a quinoline moiety that is substituted by one carboxy substituent.
organic heterotricyclic compoundAn organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms.
aromatic carboxylic acidAny carboxylic acid in which the carboxy group is directly bonded to an aromatic ring.
oxacycleAny organic heterocyclic compound containing at least one ring oxygen atom.
quinolone antibioticAn organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (27)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency39.81070.003245.467312,589.2998AID1705
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency1.99530.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency28.18385.623417.292931.6228AID2323
thioredoxin reductaseRattus norvegicus (Norway rat)Potency14.22210.100020.879379.4328AID488772; AID588453; AID588456
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency0.36933.189029.884159.4836AID1224846
SMAD family member 2Homo sapiens (human)Potency10.40940.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency10.40940.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686979
GLI family zinc finger 3Homo sapiens (human)Potency15.89610.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency55.25930.000221.22318,912.5098AID1259381
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency17.78280.011212.4002100.0000AID1030
progesterone receptorHomo sapiens (human)Potency1.23710.000417.946075.1148AID1346784
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency78.05580.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency29.84930.000229.305416,493.5996AID743079
arylsulfatase AHomo sapiens (human)Potency21.33131.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency6.23030.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency10.00000.00207.533739.8107AID891
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency19.95260.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency0.00670.006026.168889.1251AID488953
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency44.66840.050127.073689.1251AID588590
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency15.84890.251215.843239.8107AID504327
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.01780.00106.000935.4813AID943
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency7.94331.000010.475628.1838AID1457
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (214)

Assay IDTitleYearJournalArticle
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID208021Minimum inhibitory concentration against Streptococcus pneumoniae 63011990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID406639Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/363-5036 isolate containing gyrA and parC quinolone resistance mutations from Atlantic cod at 30 ug by disc diffusion assay2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1137042Antibacterial activity against Staphylococcus aureus 209P after 24 hrs by twofold dilution assay1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Studies on quinoline derivatives and related compounds. 5. Synthesis and antimicrobial activity of novel 1-alkoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID70860Compound was tested for inhibition of the gram-negative organism Escherichia cloacae HA 26461986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID406633Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/363-5036 isolate containing gyrA and parC quinolone resistance mutations from Atlantic cod after 5 days by microplate broth dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID556573Bactericidal activity against sodB gene-deficient Escherichia coli K-12 3145 at 0.4 ug/ml2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Contribution of oxidative damage to antimicrobial lethality.
AID1132709Antimicrobial activity against Mycobacterium smegmatis 607 assessed as growth inhibition by agar dilution-streak method1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Quinolone antimicrobial agents. 1. Versatile new synthesis of 1-alkyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID1137052Antibacterial activity against Escherichia coli 0111 infected in ICR mouse administered orally 0.5 hr and 6 hrs post infection measured 1 week post challenge1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Studies on quinoline derivatives and related compounds. 5. Synthesis and antimicrobial activity of novel 1-alkoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID532089Antimicrobial against Pseudomonas aeruginosa 312 harboring PBPP allele by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID205969Minimum inhibitory concentration against Staphylococcus aureus 95 (Methicillin-resistant, high-level beta-lactamase producer)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID1131087Antimicrobial activity against Proteus mirabilis Finland 9 assessed as growth inhibition by agar dilution-streak method1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Quinolone antimicrobial agents. 2. Methylenedioxy positional isomers of oxolinic acid.
AID532082Antimicrobial against Pseudomonas aeruginosa 3894 by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID532079Antimicrobial against Pseudomonas aeruginosa 32455 harboring phzS allele by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1137043Antibacterial activity against Escherichia coli NIHJ after 24 hrs by twofold dilution assay1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Studies on quinoline derivatives and related compounds. 5. Synthesis and antimicrobial activity of novel 1-alkoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID406634Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/363-5034 isolate containing gyrA and parC quinolone resistance mutations from Atlantic cod after 5 days by microplate broth dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID67230Evaluated for the minimum inhibitory concentration against Enterococcus faecalis ATCC 292121990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID1137041Drug recovery in Wistar rat urine at 50 mg/kg, po measured over 24 hrs1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Studies on quinoline derivatives and related compounds. 5. Synthesis and antimicrobial activity of novel 1-alkoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID1557097Inhibition of RyR1 harboring R2163C mutant (unknown origin) stably expressed in HEK293 cells coexpressing R-CEPIA1er assessed as suppression in Ca2+ leakage from ER prestimulated with doxycycline for 24 to 28 hrs followed by compound addition at 100 secs 2019European journal of medicinal chemistry, Oct-01, Volume: 179Structural development of a type-1 ryanodine receptor (RyR1) Ca
AID406644Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/494-5106 isolate containing parC position 83 Ser-Ile substitution mutation from Atlantic cod at 30 ug by disc diffusion assay2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID1557107Inhibition of RyR1 harboring R2163C mutant (unknown origin) stably expressed in HEK293 cells coexpressing R-CEPIA1er assessed as increase in Ca2+ level in ER prestimulated with doxycycline for 24 to 28 hrs followed by compound addition at 100 secs and mea2019European journal of medicinal chemistry, Oct-01, Volume: 179Structural development of a type-1 ryanodine receptor (RyR1) Ca
AID406640Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/363-5034 isolate containing gyrA and parC quinolone resistance mutations from Atlantic cod at 30 ug by disc diffusion assay2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID1243366Antimicrobial activity against Salmonella typhimurium ATCC 19430 incubated for 18 hrs by agar dilution method2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Novel antibacterial active quinolone-fluoroquinolone conjugates and 2D-QSAR studies.
AID67545Activity against Enterobacter aerogenes2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Search compounds with antimicrobial activity by applying molecular topology to selected quinolones.
AID1243367Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 incubated for 18 hrs by agar dilution method2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Novel antibacterial active quinolone-fluoroquinolone conjugates and 2D-QSAR studies.
AID433400Inhibition of Mycobacterium leprae wild type DNA gyrase A2B2 assessed as DNA supercoiling inhibition2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID133813Compound was evaluated for protective dose against the Streptococcus aureus UC-76 lethal infection following po administration in mouse1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1132706Antimicrobial activity against Escherichia coli 9637 assessed as growth inhibition by agar dilution-streak method1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Quinolone antimicrobial agents. 1. Versatile new synthesis of 1-alkyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID162748Minimum inhibitory concentration against Proteus mirabilis 901990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID133815Compound was evaluated for protective dose against the Streptococcus aureus UC-76 lethal infection following sc administration in mouse1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID406635Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/422-5063 isolate containing gyrA and parC quinolone resistance mutations from Atlantic cod after 5 days by microplate broth dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID532088Antimicrobial against Pseudomonas aeruginosa 3465 harboring tsaA allele by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID144443In vitro antibacterial activity against Mycobacterium smegmatis (ATCC 607)1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Structure-activity relationships among DNA gyrase inhibitors. Synthesis and biological evaluation of 1,2-dihydro-4, 4-dimethyl-1-oxo-2-naphthalenecarboxylic acids as 1-carba bioisosteres of oxolinic acid.
AID1111402Nematicidal activity against Bursaphelenchus xylophilus in pot-grown three-year-old trees of Pinus densiflora assessed as reduction of disease incidence at 10 mg/seedlings treated 7 days before inoculation measured after 1 month by measuring dead seedling2010Pest management science, Jun, Volume: 66, Issue:6
Suppression of pine wilt disease by an antibacterial agent, oxolinic acid.
AID313072Antibacterial activity against Escherichia coli2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Novel copper(II) complex of N-propyl-norfloxacin and 1,10-phenanthroline with enhanced antileukemic and DNA nuclease activities.
AID1111398Nematicidal activity against Bursaphelenchus xylophilus in pot-grown three-year-old trees of Pinus densiflora assessed as reduction of disease incidence at 10 mg/seedlings treated 7 days before inoculation measured after 1 month by measuring dead seedling2010Pest management science, Jun, Volume: 66, Issue:6
Suppression of pine wilt disease by an antibacterial agent, oxolinic acid.
AID68666In vitro antibacterial activity was determined against Escherichia coli ATCC 259221990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID433403Inhibition of Mycobacterium leprae wild type DNA gyrase subunit B D205N mutant assessed as DNA supercoiling inhibition2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID1131088Antimicrobial activity against Pseudomonas aeruginosa BMH 1 assessed as growth inhibition by agar dilution-streak method1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Quinolone antimicrobial agents. 2. Methylenedioxy positional isomers of oxolinic acid.
AID1132707Antimicrobial activity against Staphylococcus gallinarum 9184 assessed as growth inhibition by agar dilution-streak method1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Quinolone antimicrobial agents. 1. Versatile new synthesis of 1-alkyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID532084Antimicrobial against Pseudomonas aeruginosa 40198 harboring nirJ allele by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID556571Bactericidal activity against sodA gene-deficient Escherichia coli K-12 3144 at 0.4 ug/ml2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Contribution of oxidative damage to antimicrobial lethality.
AID532080Antimicrobial against Pseudomonas aeruginosa 3208 harboring phzM allele by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1131085Antimicrobial activity against Escherichia coli ATCC 26 assessed as growth inhibition by agar dilution-streak method1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Quinolone antimicrobial agents. 2. Methylenedioxy positional isomers of oxolinic acid.
AID70571Compound was tested for inhibition of the gram-negative organism Escherichia coli vogel1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID96229Compound was tested for inhibition of the gram-negative organism Klebsiella pneumoniae MGH-21986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID69784Antibacterial activity against Escherichia coli (vogel)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1131090Antimicrobial activity against Serratia marcescens ATCC 4003 assessed as growth inhibition by agar dilution-streak method1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Quinolone antimicrobial agents. 2. Methylenedioxy positional isomers of oxolinic acid.
AID556574Bactericidal activity against sodB gene-deficient Escherichia coli K-12 3145 after 2 hrs2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Contribution of oxidative damage to antimicrobial lethality.
AID324746Effect on Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as enhancement of supercoiled pBR322 DNA cleavage2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID70411In vitro for antibacterial activity against Gram-negative Escherichia coli NIJH JC-2.1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids.
AID406645Antimicrobial activity against Vibrio anguillarum BAF33487 containing parC position 90 Glu-Gly substitution mutation2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID1131084Antimicrobial activity against Acinetobacter sp. 2347 assessed as growth inhibition by agar dilution-streak method1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Quinolone antimicrobial agents. 2. Methylenedioxy positional isomers of oxolinic acid.
AID406642Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/367-5042 isolate containing gyrA and parC quinolone resistance mutations from Atlantic cod at 30 ug by disc diffusion assay2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID208894Compound was tested for inhibition of the gram-negative organism Streptococcus aureus UC-76.1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1132710Antimicrobial activity against Candida albicans 10231 assessed as growth inhibition by agar dilution-streak method1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Quinolone antimicrobial agents. 1. Versatile new synthesis of 1-alkyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID96097In vitro antibacterial activity against Klebsiella pneumoniae AD (ATCC 10031)1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Structure-activity relationships among DNA gyrase inhibitors. Synthesis and biological evaluation of 1,2-dihydro-4, 4-dimethyl-1-oxo-2-naphthalenecarboxylic acids as 1-carba bioisosteres of oxolinic acid.
AID1137047Drug level in Wistar rat serum at 50 mg/kg, po measured at 0.5 hr1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Studies on quinoline derivatives and related compounds. 5. Synthesis and antimicrobial activity of novel 1-alkoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID78707MIC at which cleaved DNA (linear) is observed at an intensity relative to oxolinic acid at 10 ug/mL by using Gyrase Induced DNA-Cleavage assay1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID163738Compound was tested for inhibition of the gram-negative organism Providencia rettgeri H17711986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1111405Nematicidal activity against Bursaphelenchus xylophilus assessed as mortality at 10 mg/l after 48 hr2010Pest management science, Jun, Volume: 66, Issue:6
Suppression of pine wilt disease by an antibacterial agent, oxolinic acid.
AID1132708Antimicrobial activity against Klebsiella pneumoniae 10031 assessed as growth inhibition by agar dilution-streak method1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Quinolone antimicrobial agents. 1. Versatile new synthesis of 1-alkyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID433404Inhibition of Mycobacterium leprae wild type DNA gyrase A2B2 assessed as formation of DNA cleavable complex2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID1243365Antimicrobial activity against Streptococcus pyogenes ATCC 19615 incubated for 18 hrs by agar dilution method2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Novel antibacterial active quinolone-fluoroquinolone conjugates and 2D-QSAR studies.
AID535849Antimicrobial against Pseudomonas aeruginosa PAO1 by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID433578Inhibition of Mycobacterium leprae wild type DNA gyrase subunit A G89A mutant assessed as formation of DNA cleavable complex2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID1111407Antibacterial activity against Serratia marcescens subsp. marcescens KRICT4 at 1.6 mg/l after 24 hr2010Pest management science, Jun, Volume: 66, Issue:6
Suppression of pine wilt disease by an antibacterial agent, oxolinic acid.
AID163773Evaluated for the minimum inhibitory concentration against Pseudomonas aeruginosa 18S/H ( Class Id beta-lactamase overproducer)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID1131092Antimicrobial activity against Staphylococcus aureus ATCC 6538P assessed as growth inhibition by agar dilution-streak method1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Quinolone antimicrobial agents. 2. Methylenedioxy positional isomers of oxolinic acid.
AID209449Minimum inhibitory concentration against Streptococcus pyogenes 41990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID186416Effect on the spontaneous locomotor activity of rats at 0-15 min upon ip administration of the compounds at a dose of 100 mg/kg.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID78688Inhibitory concentration in supercoiling inhibition Escherichia coli DNA gyrase assay1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID186546Effect on the spontaneous locomotor activity of rats at 0-60 min upon ip administration of the compouns at a dose of 100 mg/kg.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID1243364Antimicrobial activity against Staphylococcus aureus ATCC 25923 incubated for 18 hrs by agar dilution method2015Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
Novel antibacterial active quinolone-fluoroquinolone conjugates and 2D-QSAR studies.
AID532081Antimicrobial against Pseudomonas aeruginosa 3434 by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID210022Antibacterial activity against Streptococcus pneumoniae (SV-1)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID164385Antibacterial activity against Pseudomonas aeruginosa (UI-18)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID203134Evaluated for the minimum inhibitory concentration against Serratia marcescens 10711990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID200513In vitro antibacterial activity against Salmonella gallinarum (ATCC 9184)1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Structure-activity relationships among DNA gyrase inhibitors. Synthesis and biological evaluation of 1,2-dihydro-4, 4-dimethyl-1-oxo-2-naphthalenecarboxylic acids as 1-carba bioisosteres of oxolinic acid.
AID70739Evaluated for the minimum inhibitory concentration against Escherichia coli TEM-11990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID133809Compound was evaluated for protective dose against Streptococcus pneumoniae SV-1 lethal infection following sc administration; no data1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID186421Effect on the spontaneous locomotor activity of rats at 0-15 min upon po administration of the compounds at a dose of 30 mg/kg1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID1111401Nematicidal activity against Bursaphelenchus xylophilus in pot-grown three-year-old trees of Pinus densiflora assessed as reduction of disease incidence at 30 mg/seedlings treated 7 days before inoculation measured after 1 month by measuring dead seedling2010Pest management science, Jun, Volume: 66, Issue:6
Suppression of pine wilt disease by an antibacterial agent, oxolinic acid.
AID1111409Antibacterial activity against [Brevibacterium] frigoritolerans KRICT2 at 1.6 mg/l after 24 hr2010Pest management science, Jun, Volume: 66, Issue:6
Suppression of pine wilt disease by an antibacterial agent, oxolinic acid.
AID66242Evaluated for the minimum inhibitory concentration against Enterobacter cloacae P991990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID209302Compound was tested for inhibition of the gram-negative organism Streptococcus pyogenes C203.1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1137049Drug level in Wistar rat serum at 50 mg/kg, po measured at 2 hrs1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Studies on quinoline derivatives and related compounds. 5. Synthesis and antimicrobial activity of novel 1-alkoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID1111397Nematicidal activity against Bursaphelenchus xylophilus in pot-grown three-year-old trees of Pinus densiflora assessed as reduction of disease incidence at 30 mg/seedlings treated 7 days before inoculation measured after 1 month by measuring dead seedling2010Pest management science, Jun, Volume: 66, Issue:6
Suppression of pine wilt disease by an antibacterial agent, oxolinic acid.
AID186426Effect on the spontaneous locomotor activity of rats at 0-60 min upon ip administration of the compounds at a dose of 30 mg/kg1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID164709Compound was tested for inhibition of the gram-negative organism Pseudomonas aeruginosa UI-181986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID532087Antimicrobial against Pseudomonas aeruginosa 8666 by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID208893Compound was tested for inhibition of the gram-negative organism Streptococcus aureus H228.1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1557105Displacement of [3H]ryanodine from wild type RyR3 (unknown origin) stably expressed in HEK293 cells microsomes at 10 uM by radioligand binding assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Structural development of a type-1 ryanodine receptor (RyR1) Ca
AID1137050Drug level in Wistar rat serum at 50 mg/kg, po measured at 4 hrs1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Studies on quinoline derivatives and related compounds. 5. Synthesis and antimicrobial activity of novel 1-alkoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID1557102Inhibition of wild type RyR3 (unknown origin) stably expressed in HEK293 cells coexpressing R-CEPIA1er assessed as suppression in caffeine-activated Ca2+ leakage from ER at 10 uM compound addition at 100 secs and measured every 10 secs for 300 secs by flu2019European journal of medicinal chemistry, Oct-01, Volume: 179Structural development of a type-1 ryanodine receptor (RyR1) Ca
AID324754Antibacterial activity in Mycobacterium leprae infected mouse foot-pad model assessed as parasite killing after 9 months2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID69782Antibacterial activity against Escherichia coli (H560)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID1111393Nematicidal activity against Bursaphelenchus xylophilus in pot-grown three-year-old trees of Pinus densiflora assessed as reduction of disease incidence at 10% treated 3 months before inoculation measured after 9 months by measuring dead trees relative to2010Pest management science, Jun, Volume: 66, Issue:6
Suppression of pine wilt disease by an antibacterial agent, oxolinic acid.
AID133810Compound was evaluated for protective dose against the Escherichia coli vogel lethal infection following peroral administration in mouse1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID556572Bactericidal activity against sodA gene-deficient Escherichia coli K-12 3144 after 2 hrs2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Contribution of oxidative damage to antimicrobial lethality.
AID1131093Antimicrobial activity against Streptococcus faecalis ATCC 8043 assessed as growth inhibition by agar dilution-streak method1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Quinolone antimicrobial agents. 2. Methylenedioxy positional isomers of oxolinic acid.
AID406638Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/494-5106 isolate containing parC position 83 Ser-Ile substitution mutation from Atlantic cod after 5 days by microplate broth dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID1111395Nematicidal activity against Bursaphelenchus xylophilus in pot-grown three-year-old trees of Pinus densiflora assessed as reduction of disease incidence at 10% treated 3 months before inoculation measured after 9 months by measuring dead trees2010Pest management science, Jun, Volume: 66, Issue:6
Suppression of pine wilt disease by an antibacterial agent, oxolinic acid.
AID1111408Antibacterial activity against Ewingella americana KRICT5 at 1.6 mg/l after 24 hr2010Pest management science, Jun, Volume: 66, Issue:6
Suppression of pine wilt disease by an antibacterial agent, oxolinic acid.
AID164550In vitro antibacterial activity against Gram-negative Pseudomonas aeruginosa V-1.1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids.
AID532090Antimicrobial against Pseudomonas aeruginosa 46396 harboring katA allele by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID535850Antimicrobial against Pseudomonas aeruginosa 33410 harboring phoU allele by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1131091Antimicrobial activity against Shigella sonnei ATCC 9290 assessed as growth inhibition by agar dilution-streak method1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Quinolone antimicrobial agents. 2. Methylenedioxy positional isomers of oxolinic acid.
AID433402Inhibition of Mycobacterium leprae DNA gyrase subunit A A91V mutant assessed as DNA supercoiling inhibition2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID433580Inhibition of Mycobacterium leprae wild type DNA gyrase subunit B D205N mutant assessed as formation of DNA cleavable complex2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID1131089Antimicrobial activity against Salmonella typhi ATCC 9992 assessed as growth inhibition by agar dilution-streak method1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Quinolone antimicrobial agents. 2. Methylenedioxy positional isomers of oxolinic acid.
AID207175Antibacterial activity against Staphylococcus aureus (H228)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID209087Compound was tested for inhibition of the gram-negative organism Streptococcus faecalis MGH-21986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID163779Minimum inhibitory concentration against Pseudomonas aeruginosa ATCC 278531990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID406643Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/367-5043 isolate containing gyrA position 83 Ser-Ile substitution mutation from Atlantic cod at 30 ug by disc diffusion assay2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID163235Evaluated for the minimum inhibitory concentration against Proteus vulgaris 1028 BC1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID52940Evaluated for the minimum inhibitory concentration against Citrobacter freundii BS-16.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID313073Antibacterial activity against Pseudomonas aeruginosa2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Novel copper(II) complex of N-propyl-norfloxacin and 1,10-phenanthroline with enhanced antileukemic and DNA nuclease activities.
AID532078Antimicrobial against Pseudomonas aeruginosa 30848 harboring phoU allele by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID205971Minimum inhibitory concentration against Staphylococcus aureus ATCC 29213 (inducible, low level beta-lactamase producer)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID1137045Antibacterial activity against Pseudomonas aeruginosa 104 after 24 hrs by twofold dilution assay1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Studies on quinoline derivatives and related compounds. 5. Synthesis and antimicrobial activity of novel 1-alkoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID1557104Displacement of [3H]ryanodine from wild type RyR2 (unknown origin) stably expressed in HEK293 cells microsomes at 10 uM by radioligand binding assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Structural development of a type-1 ryanodine receptor (RyR1) Ca
AID324745Inhibition of Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as inhibition of pBR322 DNA supercoiling2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID324747Antibacterial activity against Mycobacterium leprae at 5 ug/mL after 11 to 18 days2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
AID186418Effect on the spontaneous locomotor activity of rats at 0-15 min upon ip administration of the compounds at a dose of 300 mg/kg.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID78709Inhibition of DNA gyrase of Escherichia coli H560 cells1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID133812Compound was evaluated for protective dose against the Escherichia coli vogel lethal infection following sc administration in mouse1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID70570Compound was tested for inhibition of the gram-negative organism Escherichia coli H5601986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID1111403Nematicidal activity against Bursaphelenchus xylophilus in pot-grown three-year-old trees of Pinus densiflora assessed as reduction of disease incidence at 3 mg/seedlings treated 7 days before inoculation measured after 1 month by measuring dead seedling 2010Pest management science, Jun, Volume: 66, Issue:6
Suppression of pine wilt disease by an antibacterial agent, oxolinic acid.
AID313074Antibacterial activity against Staphylococcus aureus2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Novel copper(II) complex of N-propyl-norfloxacin and 1,10-phenanthroline with enhanced antileukemic and DNA nuclease activities.
AID532085Antimicrobial against Pseudomonas aeruginosa 8564 harboring pyrX allele by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID433401Inhibition of Mycobacterium leprae DNA gyrase subunit A G89C mutant assessed as DNA supercoiling inhibition2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID532083Antimicrobial against Pseudomonas aeruginosa 1494 harboring phnA allele by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1132705Antimicrobial activity against Staphylococcus aureus ATCC 130709 assessed as growth inhibition by agar dilution-streak method1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Quinolone antimicrobial agents. 1. Versatile new synthesis of 1-alkyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID1131086Antimicrobial activity against Klebsiella pneumoniae ATCC 8045 assessed as growth inhibition by agar dilution-streak method1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Quinolone antimicrobial agents. 2. Methylenedioxy positional isomers of oxolinic acid.
AID1137053Antibacterial activity against Proteus mirabilis GN2425 infected in ICR mouse administered orally 0.5 hr and 6 hrs post infection measured 1 week post challenge1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Studies on quinoline derivatives and related compounds. 5. Synthesis and antimicrobial activity of novel 1-alkoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID70407In vitro antibacterial activity against Escherichia coli (ATCC 9637)1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Structure-activity relationships among DNA gyrase inhibitors. Synthesis and biological evaluation of 1,2-dihydro-4, 4-dimethyl-1-oxo-2-naphthalenecarboxylic acids as 1-carba bioisosteres of oxolinic acid.
AID1137051Drug level in Wistar rat serum at 50 mg/kg, po measured at 6 hrs1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Studies on quinoline derivatives and related compounds. 5. Synthesis and antimicrobial activity of novel 1-alkoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID186545Effect on the spontaneous locomotor activity of rats at 0-60 min upon ip administration of the compounds at a dose of 300 mg/kg.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis, antibacterial activities, and pharmacological properties of enantiomers of temafloxacin hydrochloride.
AID1137044Antibacterial activity against Proteus mirabilis GN 2425 after 24 hrs by twofold dilution assay1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Studies on quinoline derivatives and related compounds. 5. Synthesis and antimicrobial activity of novel 1-alkoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID133819Compound was evaluated for protective dose against the Streptococcus pneumoniae SV-1 lethal infection following po administration; no data1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID433579Inhibition of Mycobacterium leprae wild type DNA gyrase subunit A A91V mutant assessed as formation of DNA cleavable complex2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
AID406637Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/367-5043 isolate containing gyrA position 83 Ser-Ile substitution mutation from Atlantic cod after 5 days by microplate broth dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID1111399Nematicidal activity against Bursaphelenchus xylophilus in pot-grown three-year-old trees of Pinus densiflora assessed as reduction of disease incidence at 3 mg/seedlings treated 7 days before inoculation measured after 1 month by measuring dead seedling 2010Pest management science, Jun, Volume: 66, Issue:6
Suppression of pine wilt disease by an antibacterial agent, oxolinic acid.
AID207936In vitro antibacterial activity against Staphylococcus aureus (ATCC 13709)1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Structure-activity relationships among DNA gyrase inhibitors. Synthesis and biological evaluation of 1,2-dihydro-4, 4-dimethyl-1-oxo-2-naphthalenecarboxylic acids as 1-carba bioisosteres of oxolinic acid.
AID532086Antimicrobial against Pseudomonas aeruginosa 9256 harboring ybhO allele by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antimicrobial studies with the Pseudomonas aeruginosa two-allele library require caution.
AID1137048Drug level in Wistar rat serum at 50 mg/kg, po measured at 1 hr1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Studies on quinoline derivatives and related compounds. 5. Synthesis and antimicrobial activity of novel 1-alkoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID46902In vitro antibacterial activity against Candida albicans (ATCC 10231)1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Structure-activity relationships among DNA gyrase inhibitors. Synthesis and biological evaluation of 1,2-dihydro-4, 4-dimethyl-1-oxo-2-naphthalenecarboxylic acids as 1-carba bioisosteres of oxolinic acid.
AID1131094Antimicrobial activity against Proteus vulgaris ATCC 6897 assessed as growth inhibition by agar dilution-streak method1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Quinolone antimicrobial agents. 2. Methylenedioxy positional isomers of oxolinic acid.
AID205968Minimum inhibitory concentration against Staphylococcus aureus 1059B (inducible, high level beta-lactamase producer)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Cephalosporin 3'-quinolone esters with a dual mode of action.
AID406636Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/367-5042 isolate containing gyrA and parC quinolone resistance mutations from Atlantic cod after 5 days by microplate broth dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID210196Compound was tested for inhibition of the gram-negative organism Streptococcus pneumoniae SV-11986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
1-Ethyl-7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8-difluoro-1,4- dihydro-4-oxo-3-quinoline-carboxylic acid. New quinolone antibacterial with potent gram-positive activity.
AID95885Antibacterial activity against Klebsiella pneumonia (MGH-2)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID207933In vitro antibacterial activity against Gram-positive, Staphylococcus aureus 209 P1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids.
AID406641Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/422-5063 isolate containing gyrA and parC quinolone resistance mutations from Atlantic cod at 30 ug by disc diffusion assay2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID53450In vitro DNA gyrase inhibition activity1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Structure-activity relationships among DNA gyrase inhibitors. Synthesis and biological evaluation of 1,2-dihydro-4, 4-dimethyl-1-oxo-2-naphthalenecarboxylic acids as 1-carba bioisosteres of oxolinic acid.
AID1137046Antibacterial activity against Klebsiella pneumoniae PCI-602 after 24 hrs by twofold dilution assay1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Studies on quinoline derivatives and related compounds. 5. Synthesis and antimicrobial activity of novel 1-alkoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (419)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990219 (52.27)18.7374
1990's68 (16.23)18.2507
2000's67 (15.99)29.6817
2010's47 (11.22)24.3611
2020's18 (4.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.38 (24.57)
Research Supply Index6.16 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index80.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (50.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (3.29%)5.53%
Reviews13 (2.85%)6.00%
Case Studies9 (1.97%)4.05%
Observational0 (0.00%)0.25%
Other419 (91.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]